{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:07:54Z","timestamp":1792796874304,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.vaccine.2023.06.014","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T12:50:33Z","timestamp":1686833433000},"page":"4666-4678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S."],"prefix":"10.1016","volume":"41","author":[{"given":"Azadeh","family":"Shoaibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia C.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4825-0426","authenticated-orcid":false,"given":"Hui-Lee","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tainya C.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8020-6839","authenticated-orcid":false,"given":"Yoganand","family":"Chillarige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4691-939X","authenticated-orcid":false,"given":"Rose","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kwist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnstein","family":"Lindaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Matuska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0792-5690","authenticated-orcid":false,"given":"Michelle","family":"Ondari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Parulekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Obidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy K.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Kelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5805-2837","authenticated-orcid":false,"given":"Richard A.","family":"Forshee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2517-0271","authenticated-orcid":false,"given":"Steven A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.06.014_b0005","unstructured":"Centers for Disease Control and Prevention. Trends in Number of COVID-19 Cases and Deaths in the US Reported to CDC, by State\/Territory; 2022; https:\/\/covid.cdc.gov\/covid-data-tracker\/#trends_weeklydeaths_select_00. Accessed 1\/9\/2023."},{"key":"10.1016\/j.vaccine.2023.06.014_b0010","unstructured":"Centers for Disease Control and Prevention. New admissions of patients with confirmed COVID-19; 2023; https:\/\/covid.cdc.gov\/covid-data-tracker\/#new-hospital-admissions. Accessed 1\/9\/2023, 2023."},{"key":"10.1016\/j.vaccine.2023.06.014_b0015","unstructured":"Centers for Disease Control and Prevention. Demographic trends of COVID-19 cases and deaths in the US reported to CDC; 2022; https:\/\/covid.cdc.gov\/covid-data-tracker\/#demographics. Accessed 1\/9\/2023."},{"key":"10.1016\/j.vaccine.2023.06.014_b0020","unstructured":"Centers for Disease Control and Prevention. Overview of COVID-19 Vaccines; 2022; https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/overview-COVID-19-vaccines.html. Accessed November 30, 2022."},{"key":"10.1016\/j.vaccine.2023.06.014_b0025","unstructured":"U.S. Food and Drug Administration. Pfizer-BioNTech COVID-19 Vaccines; 2022; https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/pfizer-biontech-covid-19-vaccines. Accessed 1\/9\/2023."},{"key":"10.1016\/j.vaccine.2023.06.014_b0030","unstructured":"U.S. Food and Drug Administration. Moderna COVID-19 Vaccines; 2022; https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/moderna-covid-19-vaccines. Accessed 1\/9\/2023."},{"key":"10.1016\/j.vaccine.2023.06.014_b0035","unstructured":"U.S Food and Drug Administration. Novavax COVID-19 Vaccine, Adjuvanted; 2022; https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/novavax-covid-19-vaccine-adjuvanted. Accessed 1\/9\/2023."},{"key":"10.1016\/j.vaccine.2023.06.014_b0040","unstructured":"U.S Food and Drug Administration. Coronavirus (COVID-19) update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 vaccines for use as a booster dose; 2022; https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use. Accessed 1\/9\/2023."},{"key":"10.1016\/j.vaccine.2023.06.014_b0045","unstructured":"U.S. Food and Drug Administration. Initial results of near real-time safety monitoring of COVID-19 vaccines in persons aged 65 years and older; 2022; https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/initial-results-near-real-time-safety-monitoring-covid-19-vaccines-persons-aged-65-years-and-older. Accessed 11\/30\/2022, 2022."},{"key":"10.1016\/j.vaccine.2023.06.014_b0050","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.06.014_b0055","unstructured":"Wong Hui-Lee ZKC, Ellen Tworkoski, Mao Hu, Deborah Thompson, Patricia Lloyd, Rositsa Dimova, et al. Assessment of acute myocardial infarction, pulmonary embolism, disseminated intravascular coagulation and immune thrombocytopenia following COVID-19 vaccination; July 30, 2021; https:\/\/bestinitiative.org\/wp-content\/uploads\/2021\/09\/C-19-Vaccine-Safety-AMI-PE-DIC-ITP-Protocol-2021.pdf, 2022."},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.014_b0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.gheart.2018.08.004","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"13","author":"Thygesen","year":"2018","journal-title":"Glob Heart"},{"issue":"3","key":"10.1016\/j.vaccine.2023.06.014_b0065","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/trf.16251","article-title":"Medical chart validation of inpatient diagnosis codes for transfusion-related acute lung injury 2013\u20132015","volume":"61","author":"Fuller","year":"2021","journal-title":"Transfusion"},{"issue":"31","key":"10.1016\/j.vaccine.2023.06.014_b0070","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1016\/j.vaccine.2007.02.067","article-title":"Thrombocytopenia: Case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Wise","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2023.06.014_b0075","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1055\/s-0037-1616068","article-title":"Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation","volume":"86","author":"Taylor","year":"2001","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.vaccine.2023.06.014_b0080","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1538-7836.2007.02313.x","article-title":"The scoring system of the scientific and standardisation committee on disseminated intravascular coagulation of the international society on thrombosis and haemostasis: a 5-year overview","volume":"5","author":"Toh","year":"2007","journal-title":"J Thrombosis Haemostasis: JTH"},{"issue":"15","key":"10.1016\/j.vaccine.2023.06.014_b0085","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.vaccine.2016.05.023","article-title":"Facial nerve palsy including Bell's palsy: Case definitions and guidelines for collection, analysis, and presentation of immunisation safety data","volume":"35","author":"Rath","year":"2017","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2023.06.014_b0090","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.vaccine.2021.11.074","article-title":"Myocarditis and pericarditis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"40","author":"Sexson Tejtel","year":"2022","journal-title":"Vaccine"},{"issue":"158","key":"10.1016\/j.vaccine.2023.06.014_b0095","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc"},{"issue":"394","key":"10.1016\/j.vaccine.2023.06.014_b0100","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/01621459.1986.10478280","article-title":"Multiple imputation for interval estimation from simple random samples with ignorable nonresponse","volume":"81","author":"Rubin","year":"1986","journal-title":"J Am Stat Assoc"},{"issue":"12","key":"10.1016\/j.vaccine.2023.06.014_b0105","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1016\/j.csda.2012.04.017","article-title":"Model-based estimation of the attributable risk: a loglinear approach","volume":"56","author":"Cox","year":"2012","journal-title":"Comput Stat Data Anal"},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.014_b0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/biostatistics\/kxn013","article-title":"Case series analysis for censored, perturbed, or curtailed post-event exposures","volume":"10","author":"Farrington","year":"2009","journal-title":"Biostatistics (Oxford, England)"},{"issue":"11","key":"10.1016\/j.vaccine.2023.06.014_b0115","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1007\/s42399-020-00521-8","article-title":"Immune thrombocytopenia secondary to COVID-19: a systematic review","volume":"2","author":"Bhattacharjee","year":"2020","journal-title":"SN Comprehensive Clin Med"},{"issue":"20","key":"10.1016\/j.vaccine.2023.06.014_b0120","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.120.046941","article-title":"COVID-19 and cardiovascular disease","volume":"141","author":"Clerkin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2023.06.014_b0125","doi-asserted-by":"crossref","unstructured":"Deutch MR, Holmberg MJ, Gissel T, Hollingdal M. Pulmonary embolism after discharge for COVID-19: A report of two cases. JRSM Cardiovasc Dis 2021; 10: 20480040211034998.","DOI":"10.1177\/20480040211034998"},{"key":"10.1016\/j.vaccine.2023.06.014_b0130","article-title":"Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study","volume":"374","author":"Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.vaccine.2023.06.014_b0135","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.mayocp.2021.07.002","article-title":"Thromboembolic risk in hospitalized and nonhospitalized COVID-19 patients: a self-controlled case series analysis of a nationwide cohort","volume":"96","author":"Ho","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"10300","key":"10.1016\/j.vaccine.2023.06.014_b0140","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(21)00896-5","article-title":"Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study","volume":"398","author":"Katsoularis","year":"2021","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.vaccine.2023.06.014_b0145","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1161\/CIRCULATIONAHA.120.050809","article-title":"Acute COVID-19 and the incidence of ischemic stroke and acute myocardial infarction","volume":"142","author":"Modin","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.014_b0150","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.120.047430","article-title":"Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence","volume":"142","author":"Poissy","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2023.06.014_b0155","doi-asserted-by":"crossref","unstructured":"Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. 2021; 385(12): 1078\u20131090.","DOI":"10.1056\/NEJMoa2110475"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.014_b0160","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/M21-2452","article-title":"Association of AZD1222 and BNT162b2 COVID-19 vaccination with thromboembolic and thrombocytopenic events in frontline personnel: a retrospective cohort study","volume":"175","author":"Hviid","year":"2022","journal-title":"Ann Int Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.014_b0165","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2021.21699","article-title":"Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older","volume":"327","author":"Jabagi","year":"2022","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.vaccine.2023.06.014_b0170","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.vaccine.2023.06.014_b0175","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"27","author":"Simpson","year":"2021","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.vaccine.2023.06.014_b0180","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1016\/j.vaccine.2021.04.054","article-title":"Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)","volume":"39","author":"Welsh","year":"2021","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.014_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003926","article-title":"Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England","volume":"19","author":"Whiteley","year":"2022","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.vaccine.2023.06.014_b0190","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.17375","article-title":"Analysis of thromboembolic and thrombocytopenic events after the AZD1222, BNT162b2, and MRNA-1273 COVID-19 vaccines in 3 Nordic countries","volume":"5","author":"Dag Berild","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.014_b0195","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US From December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.06.014_b0200","unstructured":"Centers for Disease Control and Prevention. Clinical considerations: myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults; 2022; https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/myocarditis.html. Accessed 1\/9\/2023."},{"key":"10.1016\/j.vaccine.2023.06.014_b0205","doi-asserted-by":"crossref","unstructured":"Curcio R, Gandolfo V, Alcidi R, et al. Vaccine-induced massive pulmonary embolism and thrombocytopenia following a single dose of Janssen Ad26.COV2.S vaccination. Int J Infect Dis: IJID: Off Publ Int Soc Infect Dis 2022; 116: 154\u2013156.","DOI":"10.1016\/j.ijid.2021.12.345"},{"issue":"7","key":"10.1016\/j.vaccine.2023.06.014_b0210","article-title":"Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine","volume":"14","author":"Malik","year":"2021","journal-title":"BMJ Case Reports CP"},{"key":"10.1016\/j.vaccine.2023.06.014_b0215","doi-asserted-by":"crossref","unstructured":"Burn E, Li X, Delmestri A, et al. Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2: a population-based cohort analysis. medRxiv. 2021: 2021.2007.2029.21261348.","DOI":"10.1101\/2021.07.29.21261348"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.014_b0220","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10140-022-02039-z","article-title":"Incidence of pulmonary embolism in COVID-19 infection in the ED: ancestral, Delta, Omicron variants and vaccines","volume":"29","author":"Law","year":"2022","journal-title":"Emerg Radiol"},{"key":"10.1016\/j.vaccine.2023.06.014_b0225","unstructured":"U.S. Food and Drug Administration. At-Home OTC COVID-19 Diagnostic Tests. General Information About At-Home OTC COVID-19 Diagnostic Tests. Available at: https:\/\/www.fda.gov\/medical-devices\/coronavirus-covid-19-and-medical-devices\/home-otc-covid-19-diagnostic-tests."},{"key":"10.1016\/j.vaccine.2023.06.014_b0230","unstructured":"U.S. Food and Drug Administration. In Vitro Diagnostic EUAs - Antigen Diagnostic Tests for SARS-CoV-2. Individual EUAs for Antigen Diagnostic Tests for SARS-CoV-2. Available at: https:\/\/www.fda.gov\/medical-devices\/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2#IndividualEUAs."},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.014_b0235","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1473-3099(21)00451-5","article-title":"Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study","volume":"22","author":"Wan","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2023.06.014_b0240","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/jamainternmed.2021.2219","article-title":"Association of facial paralysis with mRNA COVID-19 vaccines: a disproportionality analysis using the world health organization pharmacovigilance database","volume":"181","author":"Renoud","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.vaccine.2023.06.014_b0245","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaoto.2021.1259","article-title":"Association of COVID-19 vaccination and facial nerve palsy: A case-control study","volume":"147","author":"Shemer","year":"2021","journal-title":"JAMA Otolaryngol-Head Neck Surg"},{"issue":"8","key":"10.1016\/j.vaccine.2023.06.014_b0250","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamaoto.2021.1266","article-title":"Incidence of bell palsy in patients with COVID-19","volume":"147","author":"Tamaki","year":"2021","journal-title":"JAMA Otolaryngol-Head Neck Surg"},{"key":"10.1016\/j.vaccine.2023.06.014_b0255","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac544.1531","article-title":"Risk of acute myocardial infarction, stroke and thromboembolism following COVID-19 vaccination compared to testing positive for COVID-19 infection: a nationwide cohort study of 4.6 mio individuals","volume":"43","author":"Lassen","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vaccine.2023.06.014_b0260","unstructured":"Centers for Medicare & Medicaid Services. Assessing the completeness of medicare claims data for measuring COVID-19 vaccine administration; 2022."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:27:51Z","timestamp":1759404471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23006825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":52,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0264410X23006825"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.014","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.01.19.23284803","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}